Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

NCT00506857 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: Busulfan
DRUG: Fludarabine

Sponsor

M.D. Anderson Cancer Center